Artivion saw no growth in patent filings and highest growth of 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Artivion’s patent filings and grants. Buy the databook here.
Artivion has been focused on protecting inventions in European Patent Office(EPO) with one publication in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent grants with nearly 50% of grants. The European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where Artivion is filings its patents. Among the top granted patent authorities, Artivion has 50% of its grants in European Patent Office(EPO) and 50% in United States(US).
LifeTech Scientific could be the strongest competitor for Artivion
In terms of grant share, Artivion stands in ninth position among its competitors. LifeTech Scientific and Artivion secured the top positions according to recent patent publication data.
Cardiovascular devices related patents lead Artivion portfolio
Artivion has highest number of patents in cardiovascular devices.
For comprehensive analysis of Artivion's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.